Filing Flows › Comparisons › BMRA vs IMDX
Biomerica vs Insight Molecular Diagnostics: BMRA and IMDX compared
Biomerica is the larger company: $1.3M of revenue in its latest quarter (Q1 FY27) against $239K for Insight Molecular Diagnostics (Q2 2026). Biomerica is growing faster (-8% against -54% a year earlier).
Where the money goes: BMRA and IMDX
Biomerica (BMRA) · Q1 FY27
Biomerica, Q1 FY27: revenue $1.3M (-8% year over year), operating margin -97.0%, net loss $1.2M, operating cash flow −$802K. The chart follows the revenue to costs, profit and cash.
Insight Molecular Diagnostics (IMDX) · Q2 2026
Insight Molecular Diagnostics, Q2 2026: revenue $239K (-54% year over year), net loss $11.3M, operating cash flow −$9.3M. The chart follows the revenue to costs, profit and cash.
| Biomerica (BMRA) | Insight Molecular Diagnostics (IMDX) | |
|---|---|---|
| Latest quarter | Q1 FY27 | Q2 2026 |
| Revenue | $1.3M | $239K |
| Revenue growth, Y/Y | -8% | -54% |
| Operating margin | -97.0% | n/m |
| Net earnings | −$1.2M | −$11.3M |
| Net margin | -97.4% | — |
| Operating cash flow | −$802K | −$9.3M |
Where the revenue comes from
Biomerica
- Clinical Lab: $775K (61%)
- Over-the-counter: $291K (23%)
- Contract Manufacturing: $197K (16%)
- Physician's Office: $2K (0%)
Insight Molecular Diagnostics
- Laboratory Services: $218K (91%)
- Kitted Products: $21K (9%)
Questions
Which is bigger, Biomerica or Insight Molecular Diagnostics?
Biomerica is the larger company: $1.3M of revenue in its latest quarter (Q1 FY27) against $239K for Insight Molecular Diagnostics (Q2 2026).
Is Biomerica or Insight Molecular Diagnostics growing faster?
Biomerica is growing faster (-8% against -54% a year earlier).
More: Biomerica earnings · how Biomerica makes money · Insight Molecular Diagnostics earnings · how Insight Molecular Diagnostics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 15, 2026; 10-Q filed Aug 10, 2026). Fiscal quarters can end on different dates. Not investment advice.